Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05141682 · ClinicalTrials.gov registry record · Phase 1
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
A Phase 1 study of T-cell Large Granular Lymphocyte Leukemia, sponsored by Jonathan Brammer.
- Active
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 2
- Study locations
NCT05141682: Active Phase 1 study of T-cell Large Granular Lymphocyte Leukemia, sponsored by Jonathan Brammer.
NCT05141682 is a Phase 1 study of T-cell Large Granular Lymphocyte Leukemia that is active but no longer recruiting, run by Jonathan Brammer. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05141682, a Phase 1 study of T-cell Large Granular Lymphocyte Leukemia, is active but no longer recruiting, sponsored by Jonathan Brammer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I/II trial studies the best dose, possible benefits and/or side effects of oral azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions Studied
Interventions
- DRUG Oral Azacitidine
Study Locations (2)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
What the registry record for NCT05141682 still lists
NCT05141682 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with T-cell Large Granular Lymphocyte Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Oral Azacitidine is the first listed.
NCT05141682 reports a single indexed study location in Ohio, Virginia.
Frequently Asked Questions
What is clinical trial NCT05141682 about?
NCT05141682 is a clinical study titled "Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia". This phase I/II trial studies the best dose, possible benefits and/or side effects of oral azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatment (refractory). Chemotherapy drugs, such as azacitidine, ...
What is the current status of trial NCT05141682?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2022-06-29. Estimated completion is 2026-06-30.
What conditions does trial NCT05141682 study?
This clinical trial studies the following conditions: T-cell Large Granular Lymphocyte Leukemia.
What interventions are being tested in trial NCT05141682?
The interventions under investigation include: Oral Azacitidine (DRUG).
Who is sponsoring clinical trial NCT05141682?
This trial is sponsored by Jonathan Brammer, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05141682 being conducted?
This trial has 2 study locations across Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell Large Granular Lymphocyte Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05141682's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI